LEXX — Lexaria Bioscience Share News
0.000.00%
Last trade - 00:00- $6.49m
- $2.48m
- $0.71m
Lexaria Bioscience Corp expected to post a loss of 12 cents a share - Earnings Preview
Brief: Lexaria Bioscience Says Unit Finalizes Project Agreement With Novotech
Brief: Lexaria Bioscience Files Prospectus For Resale From Time To Time By Selling Stockholder Of Up To 4.6 Million Shares Of Common Stock - SEC Filing
Lexaria Bioscience Corp expected to post a loss of 11 cents a share - Earnings Preview
Brief: Lexaria Bioscience Corp Positive Partial 12-Week Body Weight Results From Lexaria’S Glp-1 Diabetes Animal Study
Brief: Lexaria's Glp-1 Human Pilot Study #3 Begins Dosing
Brief: Lexaria Receives Independent Review Board Approval To Begin Human Pilot Study
Brief: Wayne W. Boos Reports 3.795% Stake In Lexaria Bioscience As Of Aug 31 Versus 5.79% As Of July 31 - SEC Filing
Brief: Lexaria Bioscience Says Chris Bunka, CEO, Stepping Aside For Appointment Of Richard Christopher As New CEO
Brief: Lexaria Bioscience Corp Says Entered Into Capital On Demand Sales Agreement
Brief: Lexaria Bioscience Says Preparing For Strategic Growth
Lexaria Bioscience Corp reports results for the quarter ended in May - Earnings Summary
Lexaria Bioscience Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: Lexaria Bioscience Corp Says Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Brief: Lexaria Receives New Patents For Antiviral Drug Delivery And For Treating Epilepsy
Brief: Lexaria Bioscience Awards CRO Contract For 12-Week Dehydratech GLP-1 Chronic Human Study
Lexaria Bioscience Corp expected to post a loss of 13 cents a share - Earnings Preview
Brief: Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Brief: Lexaria To Begin Diabetes, Weight Loss Animal Study WEIGHT-A24-1